IntraLinks
, a provider of critical information exchange solutions, announced an enhanced version of its SaaS-based Safety Document Exchange, a solution for safety teams that manage reporting for Serious Adverse Events (SAEs) around the world. IntraLinks’ Safety Document Exchange enables users to save time and money related to SAE intake and subsequent safety letter distribution, while adding a layer of security and control to the process. Key enhancements delivered in the new release include configurable rules-based automated workflow, intuitive organization and user-based views, and detailed compliance reporting.
Several global pharmaceutical companies, biotechs, Contract Research Organizations (CROs) and Institutional Review Boards (IRBs) have turned to IntraLinks for safety document distribution. They have found that emailing, faxing and mailing safety documents is both inefficient and expensive. Utilizing IntraLinks for Safety Document Exchange, companies establish a detailed electronic audit trail and provide an easy-to-use solution to all parties involved in a global or localized clinical trial whether it’s their own staff, investigators, or study coordinators.
Using IntraLinks, safety teams can receive SAE reports from sites, route them for review, and instantaneously distribute safety letters in a secure, online environment to all parties requiring notification, in an automated and trackable fashion. The enhanced Safety Document Exchange provides a solution that eliminates paper and manual processes:
·The new workflow automation allows IntraLinks customers to establish various automatic distribution rules for Suspected Unexpected Serious Adverse Reactions (SUSARs), based on handling requirements for different regions, IRBs, CROs and other parties that require notification, which reduces cycle time and streamlines multi-part distribution.
· Users can set preferences that allow them to view only the information that is related to their interests and in the most appropriate format. For example, a sponsor team member can choose to view safety details by compound, study or region.
· On-demand reporting capabilities allow safety teams to generate real-time compliance reports that provide a record of distribution, access, and delivery failure, which includes being able to see who received the report and when they viewed it.
IntraLinks is exhibiting at DIA’s 46th Annual Meeting in Washington, D.C., from June 14–16. IntraLinks will be at booth number 1703.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.